Wang 2017.

Study characteristics
Methods	Design: parallel Duration: 13 weeks Assessment: baseline and post‐intervention Country: China
Participants	Pain condition: knee or hip OA Population: adults aged ≥ 40 with knee or hip OA Minimum pain intensity: ≥ 4 on 0‐10 scale Inclusion criteria Outpatients of at least 40 years who meet clinical and radiographic criteria for the diagnosis of OA of the knee or hip Exclusion criteria Physical health comorbidities All psychiatric conditions including current MDD excluded Total participants randomised: 407 Age in years (mean): 60.5 Gender: 311/407 were female Pain duration in years (mean): 7.99
Interventions	Placebo n = 202 Inert Identical and matched dosing Duloxetine 60 mg n = 205 SNRI Fixed dose, forced titration
Outcomes	Pain intensity Physical function Mood Sleep Moderate pain relief Substantial pain relief PGIC AEs SAEs Withdrawal
Missing data methods	MRMM, ITT with LOCF
Funding source	Pharmaceutical: Eli Lilly and Company
Conflicts of interest	Drs Guochun Wang, LiQi Bi, Xiangpei Li, Zhijun Li, Dongbao Zhao, Jinwei Chen, and Dongyi He had no conflicts of interest to report. Drs Hector Due nas, Li Yue, Chia‐Ning Wang, and Vladimir Skljarevski, are employees and minor shareholders of Eli Lilly and Company.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Assignment to treatment groups was determined by a computer‐generated random sequence using an interactive web‐response system (IWRS)."
Allocation concealment (selection bias)	Low risk	"The IWRS was used to assign investigational product packages to each patient throughout this study."
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, identical study drugs, matched dosing
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low levels of attrition. Used ITT with both MMRM and LOCF Attrition Total: 65/407 (16.0%) Placebo: 26/202 (12.9%) Duloxetine 60 mg: 39/205 (19.0%)
Selective reporting (reporting bias)	Low risk	All outcomes match those registered prospectively on clinicaltrials.gov.
Other bias	Low risk	No other sources of bias were identified.